Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers

Agnieszka K. Witkiewicz, Abhijit Dasgupta, Sara Sammons, Ozlem Er, Magdalena B. Potoczek, Fran Guiles, Federica Sotgia, Jonathan R. Brody, Edith P. Mitchell, Michael P. Lisanti

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Here, we investigated the possible predictive value of stromal caveolin-1 (Cav-1) as a candidate biomarker for clinical outcome in triple negative (TN) breast cancer patients. a cohort of 85 TN breast cancer patients was available, with the necessary annotation and nearly 12 years of follow-up data. Our primary outcome of interest in this study was overall survival. Interestingly, TN patients with high-levels of stromal Cav-1 had a good clinical outcome, with >50% of the patients remaining alive during the follow-up period. In contrast, the median survival for TN patients with moderate stromal Cav-1 staining was 33.5 months. similarly, the median survival for TN patients with absent stromal Cav-1 staining was 25.7 months. a comparison of 5-year survival rates yields a similar pattern. TN patients with high stromal Cav-1 had a good 5-year survival rate, with 75.5% of the patients remaining alive. In contrast, TN patients with moderate or absent stromal Cav-1 levels had progressively worse 5-year survival rates, with 40% and 9.4% of the patients remaining alive. In contrast, in a parallel analysis, the levels of tumor epithelial Cav-1 had no prognostic significance. as such, the prognostic value of Cav-1 immunostaining in TN breast cancer patients is compartment-specific, and selective for an absence of Cav-1 staining in the stromal fibroblast compartment. a recursive-partitioning algorithm was used to assess which factors are most predictive of overall survival in TN breast cancer patients. In this analysis, we included tumor size, histologic grade, whether the patient received surgery, radiotherapy or chemotherapy, CK5/6, eGFR, p53 and Ki67 status, as well as the stromal Cav-1 score. This analysis indicated that stromal loss of Cav-1 expression was the most important prognostic factor for overall survival in TN breast cancer. Virtually identical results were obtained with CK5/6 (+) and/or eGFR (+) TN breast cancer cases, demonstrating that a loss of stromal Cav-1 is also a strong prognostic factor for basal-like breast cancers. Our current findings may have important implications for the close monitoring and treatment stratification of TN and basal-like breast cancer patients.

Original languageEnglish (US)
Pages (from-to)135-143
Number of pages9
JournalCancer Biology and Therapy
Volume10
Issue number2
StatePublished - Jul 15 2010

Fingerprint

Caveolin 1
Breast Neoplasms
Triple Negative Breast Neoplasms
Survival
Survival Rate
Staining and Labeling

Keywords

  • Cancer survival
  • Cancer-associated fibroblasts
  • Caveolin-1
  • Mammary tumor stroma
  • Stromal biomarkers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Molecular Medicine
  • Pharmacology

Cite this

Witkiewicz, A. K., Dasgupta, A., Sammons, S., Er, O., Potoczek, M. B., Guiles, F., ... Lisanti, M. P. (2010). Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biology and Therapy, 10(2), 135-143.

Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. / Witkiewicz, Agnieszka K.; Dasgupta, Abhijit; Sammons, Sara; Er, Ozlem; Potoczek, Magdalena B.; Guiles, Fran; Sotgia, Federica; Brody, Jonathan R.; Mitchell, Edith P.; Lisanti, Michael P.

In: Cancer Biology and Therapy, Vol. 10, No. 2, 15.07.2010, p. 135-143.

Research output: Contribution to journalArticle

Witkiewicz, AK, Dasgupta, A, Sammons, S, Er, O, Potoczek, MB, Guiles, F, Sotgia, F, Brody, JR, Mitchell, EP & Lisanti, MP 2010, 'Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers', Cancer Biology and Therapy, vol. 10, no. 2, pp. 135-143.
Witkiewicz, Agnieszka K. ; Dasgupta, Abhijit ; Sammons, Sara ; Er, Ozlem ; Potoczek, Magdalena B. ; Guiles, Fran ; Sotgia, Federica ; Brody, Jonathan R. ; Mitchell, Edith P. ; Lisanti, Michael P. / Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. In: Cancer Biology and Therapy. 2010 ; Vol. 10, No. 2. pp. 135-143.
@article{e31a606fbffc40278b48c9d1b13e798f,
title = "Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers",
abstract = "Here, we investigated the possible predictive value of stromal caveolin-1 (Cav-1) as a candidate biomarker for clinical outcome in triple negative (TN) breast cancer patients. a cohort of 85 TN breast cancer patients was available, with the necessary annotation and nearly 12 years of follow-up data. Our primary outcome of interest in this study was overall survival. Interestingly, TN patients with high-levels of stromal Cav-1 had a good clinical outcome, with >50{\%} of the patients remaining alive during the follow-up period. In contrast, the median survival for TN patients with moderate stromal Cav-1 staining was 33.5 months. similarly, the median survival for TN patients with absent stromal Cav-1 staining was 25.7 months. a comparison of 5-year survival rates yields a similar pattern. TN patients with high stromal Cav-1 had a good 5-year survival rate, with 75.5{\%} of the patients remaining alive. In contrast, TN patients with moderate or absent stromal Cav-1 levels had progressively worse 5-year survival rates, with 40{\%} and 9.4{\%} of the patients remaining alive. In contrast, in a parallel analysis, the levels of tumor epithelial Cav-1 had no prognostic significance. as such, the prognostic value of Cav-1 immunostaining in TN breast cancer patients is compartment-specific, and selective for an absence of Cav-1 staining in the stromal fibroblast compartment. a recursive-partitioning algorithm was used to assess which factors are most predictive of overall survival in TN breast cancer patients. In this analysis, we included tumor size, histologic grade, whether the patient received surgery, radiotherapy or chemotherapy, CK5/6, eGFR, p53 and Ki67 status, as well as the stromal Cav-1 score. This analysis indicated that stromal loss of Cav-1 expression was the most important prognostic factor for overall survival in TN breast cancer. Virtually identical results were obtained with CK5/6 (+) and/or eGFR (+) TN breast cancer cases, demonstrating that a loss of stromal Cav-1 is also a strong prognostic factor for basal-like breast cancers. Our current findings may have important implications for the close monitoring and treatment stratification of TN and basal-like breast cancer patients.",
keywords = "Cancer survival, Cancer-associated fibroblasts, Caveolin-1, Mammary tumor stroma, Stromal biomarkers",
author = "Witkiewicz, {Agnieszka K.} and Abhijit Dasgupta and Sara Sammons and Ozlem Er and Potoczek, {Magdalena B.} and Fran Guiles and Federica Sotgia and Brody, {Jonathan R.} and Mitchell, {Edith P.} and Lisanti, {Michael P.}",
year = "2010",
month = "7",
day = "15",
language = "English (US)",
volume = "10",
pages = "135--143",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers

AU - Witkiewicz, Agnieszka K.

AU - Dasgupta, Abhijit

AU - Sammons, Sara

AU - Er, Ozlem

AU - Potoczek, Magdalena B.

AU - Guiles, Fran

AU - Sotgia, Federica

AU - Brody, Jonathan R.

AU - Mitchell, Edith P.

AU - Lisanti, Michael P.

PY - 2010/7/15

Y1 - 2010/7/15

N2 - Here, we investigated the possible predictive value of stromal caveolin-1 (Cav-1) as a candidate biomarker for clinical outcome in triple negative (TN) breast cancer patients. a cohort of 85 TN breast cancer patients was available, with the necessary annotation and nearly 12 years of follow-up data. Our primary outcome of interest in this study was overall survival. Interestingly, TN patients with high-levels of stromal Cav-1 had a good clinical outcome, with >50% of the patients remaining alive during the follow-up period. In contrast, the median survival for TN patients with moderate stromal Cav-1 staining was 33.5 months. similarly, the median survival for TN patients with absent stromal Cav-1 staining was 25.7 months. a comparison of 5-year survival rates yields a similar pattern. TN patients with high stromal Cav-1 had a good 5-year survival rate, with 75.5% of the patients remaining alive. In contrast, TN patients with moderate or absent stromal Cav-1 levels had progressively worse 5-year survival rates, with 40% and 9.4% of the patients remaining alive. In contrast, in a parallel analysis, the levels of tumor epithelial Cav-1 had no prognostic significance. as such, the prognostic value of Cav-1 immunostaining in TN breast cancer patients is compartment-specific, and selective for an absence of Cav-1 staining in the stromal fibroblast compartment. a recursive-partitioning algorithm was used to assess which factors are most predictive of overall survival in TN breast cancer patients. In this analysis, we included tumor size, histologic grade, whether the patient received surgery, radiotherapy or chemotherapy, CK5/6, eGFR, p53 and Ki67 status, as well as the stromal Cav-1 score. This analysis indicated that stromal loss of Cav-1 expression was the most important prognostic factor for overall survival in TN breast cancer. Virtually identical results were obtained with CK5/6 (+) and/or eGFR (+) TN breast cancer cases, demonstrating that a loss of stromal Cav-1 is also a strong prognostic factor for basal-like breast cancers. Our current findings may have important implications for the close monitoring and treatment stratification of TN and basal-like breast cancer patients.

AB - Here, we investigated the possible predictive value of stromal caveolin-1 (Cav-1) as a candidate biomarker for clinical outcome in triple negative (TN) breast cancer patients. a cohort of 85 TN breast cancer patients was available, with the necessary annotation and nearly 12 years of follow-up data. Our primary outcome of interest in this study was overall survival. Interestingly, TN patients with high-levels of stromal Cav-1 had a good clinical outcome, with >50% of the patients remaining alive during the follow-up period. In contrast, the median survival for TN patients with moderate stromal Cav-1 staining was 33.5 months. similarly, the median survival for TN patients with absent stromal Cav-1 staining was 25.7 months. a comparison of 5-year survival rates yields a similar pattern. TN patients with high stromal Cav-1 had a good 5-year survival rate, with 75.5% of the patients remaining alive. In contrast, TN patients with moderate or absent stromal Cav-1 levels had progressively worse 5-year survival rates, with 40% and 9.4% of the patients remaining alive. In contrast, in a parallel analysis, the levels of tumor epithelial Cav-1 had no prognostic significance. as such, the prognostic value of Cav-1 immunostaining in TN breast cancer patients is compartment-specific, and selective for an absence of Cav-1 staining in the stromal fibroblast compartment. a recursive-partitioning algorithm was used to assess which factors are most predictive of overall survival in TN breast cancer patients. In this analysis, we included tumor size, histologic grade, whether the patient received surgery, radiotherapy or chemotherapy, CK5/6, eGFR, p53 and Ki67 status, as well as the stromal Cav-1 score. This analysis indicated that stromal loss of Cav-1 expression was the most important prognostic factor for overall survival in TN breast cancer. Virtually identical results were obtained with CK5/6 (+) and/or eGFR (+) TN breast cancer cases, demonstrating that a loss of stromal Cav-1 is also a strong prognostic factor for basal-like breast cancers. Our current findings may have important implications for the close monitoring and treatment stratification of TN and basal-like breast cancer patients.

KW - Cancer survival

KW - Cancer-associated fibroblasts

KW - Caveolin-1

KW - Mammary tumor stroma

KW - Stromal biomarkers

UR - http://www.scopus.com/inward/record.url?scp=77955443486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955443486&partnerID=8YFLogxK

M3 - Article

C2 - 20431349

AN - SCOPUS:77955443486

VL - 10

SP - 135

EP - 143

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 2

ER -